Caris Life Sciences, Inc. (CAI) — Stock Price, Chart & Analysis
Caris Life Sciences, Inc. (CAI) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $8.90B and a trailing P/E ratio of 3.20. Over the past 52 weeks, CAI has traded between $14.19 and $33.66. Caris Life Sciences, Inc. does not currently pay a regular dividend. View the live CAI chart, technical opinion, analyst ratings, fundamentals and latest news below.
Caris Life Sciences, Inc. (CAI) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $8.90B |
| P/E ratio (TTM) | 3.20 |
| EPS (TTM) | $9.83 |
| 52-week high | $33.66 |
| 52-week low | $14.19 |
| Avg. volume | 4.80M |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Caris Life Sciences, Inc. (CAI)
How much does one share of Caris Life Sciences, Inc. cost?
As of the latest update, one share of Caris Life Sciences, Inc. (CAI) trades at $100 (+0.00% today).
What is Caris Life Sciences, Inc.'s market cap?
Caris Life Sciences, Inc. has a market capitalization of approximately $8.90B.
What is Caris Life Sciences, Inc.'s P/E ratio?
Caris Life Sciences, Inc. has a trailing price-to-earnings (P/E) ratio of 3.20.
What is Caris Life Sciences, Inc.'s earnings per share (EPS)?
Caris Life Sciences, Inc.'s trailing twelve-month EPS is $9.83.
Does Caris Life Sciences, Inc. pay a dividend?
Caris Life Sciences, Inc. does not currently pay a regular dividend.
What is Caris Life Sciences, Inc.'s 52-week trading range?
Over the past year, CAI has traded between $14.19 and $33.66.
What is the analyst price target for Caris Life Sciences, Inc.?
The mean analyst price target for Caris Life Sciences, Inc. is $28.15. This is informational only and not investment advice.
Latest Caris Life Sciences, Inc. (CAI) news
- Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A LookNews · Sep 22, 2026
- Caris Life Sciences Stock Jumped 10% Yesterday. Here’s Where Shares Could Go Further in 2026.News · Sep 18, 2026
- Could Caris Life Sciences (CAI) Be 7% Undervalued After Its Lung Cancer Research Update?News · Sep 6, 2026
- Caris Life Sciences (CAI) Will Present Seven Studies At A Global Lung ConferenceNews · Sep 5, 2026
- Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung CancerNews · Sep 2, 2026
- Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic CancerNews · Aug 27, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live CAI dashboard…